miLung: accessible screening will reduce lung cancer mortality
early cancer detection
Cancer screening sensitivity has been a considerable challenge for traditional liquid biopsies, which measure tumor-derived biomarkers that are present in very low concentrations in early-stage disease. In contrast, miLung utilizes a unique approach that integrates biomarkers originating from both the tumor and the host immune system.
The immune system serves as an amplifier of cancer signal and allows us to report improved sensitivity for the detection of early-stage lung cancers, with overall performance equivalent to LD-CT.
- unique approach improves sensitivity of blood-based lung cancer screening
- ease of use will facilitate increased participation in screening and reduce lung cancer mortality
miRisk: biomarkers can guide optimal immunotherapy use in lung cancer
response prediction
Immunotherapy has revolutionized the treatment of late-stage lung cancer, however, its efficacy is notoriously unpredictable.
miRisk is a blood-based complementary diagnostic under development to address this problem in advanced-stage non-small cell lung cancer (NSCLC).
The advantage of our approach is evident as it captures immune biomarkers that reflect the peripheral immunophenotype, which is increasingly implicated in determining the outcomes of immunotherapy.
- objectively guides optimal use of immunotherapy with or without chemotherapy in NSCLC patients
- potential to stratify patients recruited into trials investigating novel immunotherapy combinations
miTrack: post-treatment follow-up aided by non-invasive tracking of cancer
treatment monitoring
Regular follow-up is part of routine care for all cancer patients to monitor treatment response and identify tumor recurrence. Regular PET and/or CT scans are the corner-stone of monitoring for lung cancer; however, these tests often cannot detect the earliest signs of recurrence and carry a risk associated with repeated exposure to ionizing radiation. Early detection of molecular recurrence is critical in determining optimal patient management strategies and improving outcomes.
With miTrack, we are developing a non-invasive blood-based diagnostic to detect molecular signs of disease recurrence or progression early and thus enable timely intervention to optimize outcomes in patients with late-stage lung cancer.
- lung cancer subtype and treatment type agnostic
- without prior tumor genomics analysis
- digital PCR-based
blood tests that go beyond the surface
applications beyond lung cancer
outlook
mirCator's versatile platform technology shows promising potential for developing solutions across various disease areas, with encouraging data supporting its application for Alzheimer's, Parkinson's, and other neurodegenerative diseases.
